Phase I, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Icotinib Combined With Gemcitabine as First-line Treatment in Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2019
Price : $35 *
At a glance
- Drugs Icotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
- 14 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 14 Jul 2015 Planned primary completion date changed to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 14 Jul 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.